Want to see HK:2511 full AI Analyst Report?
Hightide Therapeutics Inc (2511) Ratios
Hightide Therapeutics Inc Ratios
HK:2511's free cash flow for Q2 2026 was $-109.92M. For the 2026 fiscal year, HK:2511's free cash flow was decreased by $-272.30K and operating cash flow was $-109.65M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.41 | 4.67 | 9.76 | 0.64 | 27.17 |
| Quick Ratio | 5.41 | 4.67 | 9.76 | 0.64 | 27.17 |
| Cash Ratio | 2.36 | 2.83 | 7.62 | 0.31 | 26.82 |
| Solvency Ratio | -1.28 | -0.00 | -11.23 | -0.14 | -0.21 |
| Operating Cash Flow Ratio | -1.70 | -2.68 | -4.61 | -0.13 | -3.10 |
| Short-Term Operating Cash Flow Coverage | -5.14 | -6.28 | -105.05 | -0.14 | -12.63 |
| Net Current Asset Value | $ 345.66M | $ 377.61M | $ 686.49M | $ -487.36M | $ -277.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.23 | 0.14 | 0.02 | 1.48 | 1.30 |
| Debt-to-Equity Ratio | 0.41 | 0.18 | 0.02 | -2.70 | -3.72 |
| Debt-to-Capital Ratio | 0.29 | 0.16 | 0.02 | 1.59 | 1.37 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.02 | 0.00 | 0.00 | 1.37 |
| Financial Leverage Ratio | 1.80 | 1.32 | 1.13 | -1.82 | -2.86 |
| Debt Service Coverage Ratio | -6.25 | -0.01 | -262.68 | -0.18 | -11.44 |
| Interest Coverage Ratio | -97.09 | -0.29 | -1032.57 | -530.71 | -29.17 |
| Debt to Market Cap | 0.09 | 105.50 | 0.66 | 225.36 | 195.16 |
| Interest Debt Per Share | 0.27 | 175.72 | 34.91 | 2469.47 | 1975.16 |
| Net Debt to EBITDA | 0.49 | 524.17 | 0.57 | -3.76 | -1.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 105.64% | 100.07% | 100.01% | 100.02% | 100.04% |
| EBT Per EBIT | 103.72% | 85.78% | 227.40% | 84.13% | 167.37% |
| Return on Assets (ROA) | -44.41% | -0.07% | -130.55% | -22.23% | -28.45% |
| Return on Equity (ROE) | -79.76% | -0.09% | -147.69% | 40.43% | 81.37% |
| Return on Capital Employed (ROCE) | -49.33% | -0.10% | -63.81% | 50.78% | -17.64% |
| Return on Invested Capital (ROIC) | -45.45% | -0.09% | -63.28% | -27.85% | -17.47% |
| Return on Tangible Assets | -44.41% | -0.07% | -130.55% | -22.23% | -28.45% |
| Earnings Yield | -19.27% | -70.80% | -19583.07% | -3380.65% | -4260.94% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.07 | 0.06 | 0.26 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -5509.56 | -6088.17 | -1421.76 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 5509.56 | 6088.17 | 1421.76 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.35 | -652.13 | -760.56 | -335.51 | -171.74 |
| Free Cash Flow Per Share | -0.35 | -662.40 | -762.40 | -335.87 | -175.07 |
| Dividend Paid and CapEx Coverage Ratio | -2255.49 | -63.46 | -415.40 | -924.25 | -51.51 |
| Capital Expenditure Coverage Ratio | -2255.49 | -63.46 | -415.40 | -924.25 | -51.51 |
| Operating Cash Flow Coverage Ratio | -1.32 | -3.78 | -22.38 | -0.14 | -0.09 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.14% | -55534.13% | -6953.75% | -3072.48% | -1736.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.20 | -1.41 | -0.01 | -0.03 | -0.02 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.14 | 0.00 | 0.01 | -0.01 | -0.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.61 | -0.00 | -0.01 | -0.03 | -0.06 |
| Price-to-Operating Cash Flow Ratio | -7.62 | -0.00 | -0.01 | -0.03 | -0.06 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | 0.02 | -0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -5.36 | 522.96 | 0.57 | -3.79 | -1.92 |
| Enterprise Value | 1.17B | -232.31M | -586.48M | 869.90M | 253.51M |
| EV to EBITDA | -5.36 | 522.96 | 0.57 | -3.79 | -1.92 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.98 | 0.78 | 1.59 | -5.03 | -2.81 |
| EV to Operating Cash Flow | -6.98 | 0.79 | 1.60 | -5.04 | -2.87 |
| Tangible Book Value Per Share | 0.76 | 938.27 | 1453.75 | -914.05 | -531.63 |
| Shareholders’ Equity Per Share | 0.64 | 938.27 | 1453.75 | -914.05 | -527.95 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.51 | -0.84 | -2147.05 | -369.56 | -429.60 |
| Tax Burden | 1.06 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 0.86 | 1.00 | 0.82 | 1.67 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.72 | 0.71 | 0.35 | 0.89 | 0.41 |
Currency in CNY